Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Stratos Genomics, a biotechnology company based in Seattle, Washington, specializes in developing innovative genome sequencing technology. Their primary focus is on the Sequencing by Expansion (SBX) method, a single-molecule detection process that aims to overcome limitations in existing sequencing technologies. Founded with a mission to advance genomic research, Stratos Genomics has made significant strides in the field of biotechnology.
The company's unique approach to genome sequencing has attracted attention within the scientific community and from investors. Throughout its history, Stratos Genomics raised a total of $53.2 million in funding, demonstrating confidence in its potential to revolutionize genomic research and applications.
In a significant development, Stratos Genomics was acquired by Roche on June 1st, 2020. The terms of this acquisition were not publicly disclosed. This acquisition by a major pharmaceutical company highlights the value and potential of Stratos Genomics' technology in the broader healthcare and life sciences landscape.
Given the company's acquisition by Roche, there are currently no indications or reports regarding potential IPO plans for Stratos Genomics. As a subsidiary of a larger corporation, the company's future strategic decisions, including any possibilities of going public, would likely be influenced by Roche's overall corporate strategy. We will continue to monitor any developments or announcements regarding Stratos Genomics' status and future plans within the Roche organization.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Stratos Genomics' IPO prospects remain uncertain, investors eager to explore opportunities in the genomics and biotechnology space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the genomics industry, like Stratos Genomics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of innovative companies in the biotechnology sector before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
